Insights

Alzheimer’s Disease Clinical Trials

Innovative laboratory solutions to accelerate progress

Alzheimer’s disease (AD) remains an area of severe unmet need and decades of research have yet to deliver validated diagnostics to evaluate disease progression. In 2021, only one marketed drug aimed at addressing underlying disease biology, has received conditional FDA approval.

Download our insight brief and learn about the potential to advance Alzheimer’s Disease trials through advanced neurodegenerative disease reference testing services and validation of innovative diagnostic biomarkers.

Authors:
Joseph Sebastian, Ph.D., Scientific Advisor, Q2 Solutions
Tiffany W. Chow, MD, MS, Sr. Medical Strategy Lead, IQVIA